Genycell Biotech

What Genycell Biotech does

Genycell Biotech España SL is a Spain-based (Santa Fe, Granada) specialty life-sciences company that distributes genetic diagnostic products and provides technical services to clinical genetics laboratories, research institutions, and private healthcare companies across Spain and Portugal. The company's portfolio is built around three core technology platforms: NGS-based human DNA sequencing and non-invasive prenatal testing (NIPT) via CLARIGO technology, SALSA MLPA and digitalMLPA kits distributed from MRC Holland for copy-number variation and point-mutation detection, and SALSA MELT assays for rapid variant screening (including the MC002 SMA Newborn Screen). These are complemented by molecular biology services (extraction, purification, amplification), CGH microarray, cytogenetics, FISH, QF-PCR, and cell biology services using CELLnTEC media.

The business model combines product distribution (NGS reagents, MLPA/digitalMLPA kits, extraction kits, PCR polymerases), technical advisory and Field Application support, and equipment lending or rental of Illumina MiSeq and NextSeq500 sequencers and aCGH scanners to laboratories that lack capital for direct purchase. Genycell was the first entity to implement NGS as routine clinical diagnostics in Spain, acquiring the first MiSeq for that purpose in 2012, and has since built a customer base of more than 50 public and private laboratories. The company holds ISO 9001:2015 and ISO 14001 certifications and operates sales-led, with offices in Granada (headquarters), Madrid, and Valencia.

Since 2020, Genycell has operated as a subsidiary within the Health in Code group, a Spanish clinical genomics platform formed through the combination of four companies, backed by Alantra Private Equity and Mérieux Equity Partners, with stated targets to reach €100M in revenue within five years and to become a European leader in clinical genomics.

Name

Genycell Biotech

Legal name

Genycell Biotech España SL

Website

https://genycell.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Genycell Biotech is a Spanish specialty distributor and technical-services provider of genetic diagnostic products (NGS, MLPA, digitalMLPA, MELT) and equipment lending programs, serving more than 50 clinical genetics laboratories across Spain and Portugal as a subsidiary of Health in Code.

Ownership category

akta.pro rank

Product category

Clinical Genetic Diagnostics

NAICS

Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Genetic diagnostics services
• Next generation sequencing
• Molecular biology reagents
• Clinical genomics solutions
• MLPA copy number analysis

Headquarters

HQ city

Granada

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Products Distribution: Distribution of genetic diagnostic products including NGS reagents, MLPA kits, extraction and purification systems, PCR polymerases, and master mixes for DNA analysis.
2. Technical Services: Technical advisory services, Field Application support, technology implementation consulting, laboratory setup assistance, and continuous training for clients implementing genetic diagnostic techniques.
3. Equipment Rental/Leasing: Equipment lending programs and rental arrangements for sequencing equipment (MiSeq, NextSeq500) and aCGH scanners for laboratories without capital for large equipment investments.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Genycell Biotech provides genetic diagnostic products, services, and technologies to institutions, private companies, and public organizations in Spain and Portugal for R&D and clinical genetic diagnosis. Core offerings include NGS services (including Non-Invasive Prenatal Diagnosis via CLARIGO), distribution of MLPA and digitalMLPA kits from MRC Holland, SALSA MELT assays, molecular biology reagents and services, and complementary techniques such as aCGH microarrays, cytogenetics, FISH, and QF-PCR. The company also offers laboratory setup advisory, Field Application technical support, and equipment lending programs for Illumina sequencers.

Product overview

Genycell Biotech provides an integrated portfolio of genetic diagnostic products and services for clinical and research laboratories in Spain and Portugal. The core offering centers on three main technology platforms: NGS (Next Generation Sequencing) for comprehensive human DNA sequencing and Non-Invasive Prenatal Testing (NIPT) via CLARIGO technology; MLPA and digitalMLPA (from MRC Holland) for copy number variation (CNV) detection using Coffalyser analysis software; and SALSA MELT assays for rapid variant screening. These are complemented by specialized applications including CGH microarray (prenatal, postnatal, oncohematology, preimplantation), cytogenetics/karyotyping, FISH, QF-PCR for aneuploidy screening, cell biology services with CELLnTEC media, and molecular biology services covering DNA extraction, purification, and amplification. The company also provides laboratory setup advisory services and equipment lending programs.

Differentiator

Problem solved

Functional benefit

Products and services

• NGS (Next Generation Sequencing) Services Next Generation Sequencing services for human DNA for research and clinical genetic diagnosis of diseases including breast and ovarian cancer, colon cancer, cystic fibrosis, metabolic diseases, cardiovascular diseases, hearing loss, autism, and epilepsy, including Non-Invasive Prenatal Diagnosis (NIPT) via CLARIGO technology.
• MLPA (Multiplex Ligation-dependent Probe Amplification) Products Reference technique for studying copy number variations (CNVs) associated with diseases. The optimized PCR-multiplex-based method detects deletions and duplications in up to 60 DNA sequences in a single reaction without primer bias. MS-MLPA variant detects both DNA copy number and methylation status. Distributed under partnership with MRC Holland.
• digitalMLPA Products Multiplex PCR followed by Illumina-based amplicon quantification for detection of copy number variations (CNVs) and specific point mutations. Up to 1000 unique sequences can be detected and quantified in a single reaction, combining with NGS libraries for simultaneous CNV and sequence analysis. Distributed under partnership with MRC Holland.
• SALSA MELT Assays Rapid and reliable screening assays for a small number of targets across large sample sets. First product is SALSA MC002 SMA Newborn Screen for spinal muscular atrophy screening, delivering results in approximately 4 hours from dried blood spot samples without DNA purification.
• Molecular Biology Services and Reagents DNA extraction, purification, and amplification services covering nucleic acid extraction from blood, swabs, blood-spots, post-PCR, post-gel electrophoresis, cell cultures, plasmids, and cosmids. Includes polymerases and master mix for standard, Hot Start, and room-temperature-stable quantitative PCR.
• CGH Microarray (aCGH) Services Comparative Genomic Hybridization microarray technique providing extensive genetic information across the entire human genome through thousands of analysis points. Available in BAC arrays, oligo arrays, and oligo+SNP arrays for prenatal, postnatal, oncohematology, and preimplantation (PGS) applications.
• Cytogenetics Services Study of chromosomal load in patient cells through cell culture, stimulation of cell division, and karyotype analysis to detect aneuploidies (trisomies, monosomies), deletions, duplications, and balanced or unbalanced translocations.
• FISH (Fluorescent In Situ Hybridization) Services Semi-molecular technique for illuminating DNA sections within a cell using fluorescent-labeled complementary DNA probes. Applicable to metaphase or interphase cells for detecting sub-telomeric, centromeric, painting, microdeletion, hematology, and solid tumor probes.
• QF-PCR (Quantitative Fluorescent PCR) Services Molecular technique using microsatellite markers for diagnosis of aneuploidies in chromosomes 13, 18, 21, X, and Y through evaluation of copy number at multiple loci.
• Cell Biology Services and Culture Media Cell culture services including basic and supplemented culture media, sera, and components. 20-year partnership with Swiss company CELLnTEC providing tissue-specific culture media for human, mouse, and dog cells from skin, respiratory tract, cornea, breast, bladder, and oral tissues, including 3D differentiation capabilities.
• digitalMLPA Disease Panels (NXtec) Disease-specific digitalMLPA panels including NXtec D001 Hereditary Cancer Panel 1 (28 oncogenes for hereditary cancer predisposition), NXtec D006 Multiple Myeloma (CNVs in chromosome arms and genes including TP53, MYC, IKZF1/3, BCMA), and NXtec D007 Acute Lymphoblastic Leukemia (73 genes and 8 chromosomal regions).
• Laboratory Setup Advisory Services Complete and personalized consulting from initial technology selection and setup to implementation of necessary protocols for internationalization of any clinical application. Field Application team provides technical support and continuous training for customers.
• Sequencing Equipment Lending and Rental Programs Equipment lending programs and rental arrangements for Illumina MiSeq and NextSeq500 sequencing equipment and aCGH scanners for laboratories without capital for large equipment investments. Nearly 10 equipment lending programs in hospitals and reference centers.

Quantifiable outcome

• NGS implemented as routine diagnostic in over 50 public and private laboratories in Spain and Portugal
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• MRC HollandcoreTechnology or IntegrationMRC Holland is the manufacturer of SALSA MLPA and digitalMLPA products, which are reference techniques for detecting copy number variations (CNVs) and point mutations. Genycell Biotech distributes these products in Spain and Portugal.
• IlluminacoreTechnology or IntegrationIllumina provides sequencing equipment (MiSeq, NextSeq500) and technology. Genycell Biotech has own Illumina sequencing equipment and distributes related products.
• Health in Code SLcoreStrategic or Co-development PartnerGenycell Biotech is part of Health in Code group, a Spanish clinical genomics platform formed in 2020 through the combination of four companies. Health in Code targets €100 million revenue within five years to become a European leader in clinical genomics.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regional players

• qGenomics: Barcelona-based clinical genomics laboratory offering NGS-based diagnostic testing and cytogenetics to hospitals, directly overlapping with Genycell's clinical-genetic-diagnostic service portfolio in Iberia.
• NIMGenetics: Madrid-based clinical genetics and genomics company providing NGS diagnostics, prenatal screening, and cytogenetics services across Spain and Latin America, with overlapping menu and customer profile.
• Igenómica: Spanish molecular genetics and pharmacogenomics service provider offering genetic diagnostics and personalized-medicine testing, competing for the same clinical and research-lab segment in Iberia.
• Sistemas Genómicos: Valencia-based genetic diagnostics and molecular cytogenetics laboratory (now part of ASCIRES) offering NGS, MLPA-adjacent techniques and aCGH services, competing for the same Spanish hospital and reference-lab customers as Genycell.

Broad incumbents

• QIAGEN: Global molecular biology and NGS sample-prep / bioinformatics tools provider; competes with Genycell's reagent distribution activities and broad portfolio offering for clinical and research laboratories.
• Eurofins Genomics: Global genomics services arm of Eurofins Scientific offering NGS, Sanger sequencing, oligonucleotides and molecular biology services across Europe; a broad incumbent that competes with Genycell across multiple assay categories.
• Illumina: Global sequencing platform provider whose MiSeq/NextSeq500 equipment underpins Genycell's NGS services; an incumbent supplier-cum-competitor that could bypass distributors with its own clinical offerings (e.g., Illumina Connected Software).

Direct peers

• Health in Code SL: Parent operating company in the same group providing clinical genomics services across Europe; shares headquarters (Biohub VLC Valencia) and joint data-controller status, operating an overlapping clinical-genetic-testing and bioinformatics offering.

Others

• MRC Holland: Manufacturer of SALSA MLPA, digitalMLPA and MELT kits — Genycell's core distributed product line — and a strategic technology partner rather than competitor; relevant for assessing supply-side concentration risk.

Emerging players

• Veritas Intercontinental: Iberia-focused genetic testing company offering whole-genome and NIPT services with a myGenome product line; emerging player overlapping with Genycell's NIPT and hereditary-disease NGS offerings in the same regional market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/genycell

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genycell Biotech